论文部分内容阅读
非肌层浸润性膀胱癌(NMIBC)经过手术切除及术后膀胱灌注治疗后,仍有部分患者出现肿瘤复发。然而,目前尚未完全探明导致肿瘤化疗耐药和肿瘤复发的分子机制。本研究发现,在高分级或复发的NMIBC患者的病理组织中DAB2IP的表达显著下调,与Twist1基因(一种碱性“螺旋-环-螺旋”转录因子)的表达呈负相关,患者的预期无复发生存期更短。从直观的机制上讲,DAB2IP(一种RASGTP酶激活蛋白)可能抑制STAT3的磷酸化和反式激活,
Non-muscle invasive bladder cancer (NMIBC) after surgical resection and postoperative bladder irrigation treatment, there are still some patients with tumor recurrence. However, the molecular mechanisms that lead to chemotherapy resistance and tumor recurrence have not yet been fully elucidated. This study found that the expression of DAB2IP was significantly down-regulated in the pathological tissues of patients with high grade or recurrent NMIBC and negatively correlated with the expression of Twist1 gene (a basic “helix-loop-helix” transcription factor) No recurrence is expected to be shorter. Intuitively, DAB2IP, a RASGTPase-activating protein, may inhibit the phosphorylation and transactivation of STAT3,